It’s all in your skinny genes

In the largest genome-wide association study of its kind, catchily called STILTS (Study Into Lean and Thin Subjects), Sadaf Farooqi’s team in Cambridge have reported that slim people have a favourable genetic profile compared to those at the obese end of the spectrum.

Genetic architecture of human thinness compared to severe obesity
https://doi.org/10.1371/journal.pgen.1007603

Canagliflozin and Cardiovascular and Renal Events: NEJM

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.

doi:10.1056/NEJMoa1611925

 

Semaglutide and CV Outcomes

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375:1834-1844

In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semaglutide.

http://www.nejm.org/doi/full/10.1056/NEJMoa1607141

Testosterone in the spotlight

A couple of recent articles in The BMJ that cast the spotlight on prescribed and illicit use of testosterone

Testosterone supplementation for “low T” is not supported by evidence, review concludes

BMJ 2016; 354 doi: http://dx.doi.org/10.1136/bmj.i5166 (Published 22 September 2016) Cite this as: BMJ 2016;354:i5166

Anabolic steroid use

BMJ 2016; 355 doi: http://dx.doi.org/10.1136/bmj.i5023 (Published 13 October 2016) Cite this as: BMJ 2016;355:i5023